A PYMNTS Company

Japan/UK: Takeda will buy Shire in a US$62b deal

By  |  May 8, 2018

Takeda Pharma agreed to buy London-listed Shire for £45.3 billion (US$61.50 billion) on Tuesday, May 8, after the Japanese company raised the amount of cash in its offer to US$30.33 cash and 0.839 shares of Takeda per share of Shire to secure a recommendation, reported The Wall Street Journal.

The deal will be the largest overseas acquisition by a Japanese company and propel Takeda, led by Frenchman Christophe Weber, into the top ranks of global drugmakers.

“Together, we will be a leader in providing targeted treatments in gastroenterology, neuroscience, oncology, rare diseases and plasma-derived therapies,” he said.

The tie-up will also be one of the largest ever in the pharmaceuticals sector, reported WSJ.

Full Content: Wall Street Journal

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.